Mahana Therapeutics Secures $61 Million Series B Financing To Support Commercialization And Further Development Of Digital Therapeutics
Mahana Therapeutics Secures $61 Million Series B Financing To Support Commercialization And Further Development Of Digital Therapeutics
08/11/21, 12:10 PM
Location
san franciscoMoney raised
$61 million
Round Type
series b
Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower patients with chronic health conditions, has completed a $61 million Series B financing. The company will use the funds to launch the FDA-cleared prescription digital therapeutic MahanaTM IBS and accelerate development of several digital therapeutics for chronic health conditions.
Company Info
Location
san francisco, california, united states
Additional Info
Mahana Therapeutics is a leading developer of effective prescription digital therapeutics that are designed to empower patients with chronic conditions to live fuller lives. The Company’s first product, Mahana IBS, is the first digital therapeutic to receive FDA clearance for the treatment of IBS and provides cognitive behavioral therapy (CBT) to adults with IBS. More information is available at www.MahanaTx.com.
1 Everitt HA, Landau S, O’Reilly G et al. Assessing Telephone-Delivered Cognitive-Behavioural Therapy (CBT) and Web-Delivered CBT versus Treatment as Usual in Irritable Bowel Syndrome (ACTIB): A Multicenter Randomised Trial. Gut 2019;0:1-11. Doi:10.1136/gutjnl-2018-317805.
2 Drossman DA, Morris CA, Schneck S, et al. J Clin Gastroenterol. 2009 July; 43(6): 541–550.
3 Shah ED, Salwen-Deremer JK, Gibson PR et al. Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis. MDM Policy Pract. 2021 Jan 18;6(1):2381468320978417. doi: 10.1177/2381468320978417. PMID: 33521290; PMCID: PMC7818007.